Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. due to allegations of materially misleading business information [1] Group 1: Legal Actions and Investigations - Shareholders who purchased Telix securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2] - On July 22, 2025, Telix received a subpoena from the U.S. Securities and Exchange Commission regarding disclosures related to its prostate cancer therapeutic candidates [3] - Following the subpoena news, Telix's American Depositary Receipt (ADR) price fell by $1.70, or 10.44%, closing at $14.58 per ADR on July 23, 2025 [3] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4] - In 2019, Rosen Law Firm secured over $438 million for investors, and has been consistently ranked among the top firms for securities class action settlements since 2013 [4]
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights